So Much for Leaving Abortion Up to the States

Louisiana filed a lawsuit against the U.S. Food and Drug Administration (FDA) on March 6, 2024, challenging the agency's approval of mifepristone, an abortion medication. The state argues that the FDA exceeded its authority by approving the drug and that its use poses significant health risks to women. This legal challenge, filed in federal court, seeks to revoke the FDA's 2000 approval of mifepristone and its subsequent updates, including the expansion of access through telehealth and mail delivery. Louisiana's Attorney General, Liz Murrill, stated that the lawsuit aims to hold the FDA accountable for what she described as an "unlawful approval process." The case is seen as a significant legal battle that could have broad implications for federal regulatory power and access to reproductive healthcare nationwide, potentially impacting states beyond Louisiana.